%0 Journal Article
%T COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.
%A Azad N
%A Hu Z
%A Sahin I
%A Iyer R
%A Aranha O
%A Hochster H
%A Pathak P
%A Paulson AS
%A Kalyan A
%A Liao CY
%A Tran N
%A Kelley RK
%A Heestand G
%A Cosgrove D
%A El-Khoueiry A
%A Borad M
%A Gabrail NY
%A Majeed U
%A Du L
%A Kamath S
%A Shumway N
%A Shroff R
%A Goyal L
%A Rosales M
%A Javle M
%J Future Oncol
%V 0
%N 0
%D 2024 Jun 4
%M 38861293
%F 3.674
%R 10.1080/14796694.2024.2351351
%X Treatment options for patients with biliary tract cancer are limited, and the prognosis is poor. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in patients with advanced cancers as both a monotherapy and in combination with chemotherapy. In a phase II study of patients with advanced biliary tract cancer who had received one or two prior therapies, CTX-009 with paclitaxel demonstrated a 37.5% overall response rate (ORR). Described here is the design of and rationale for COMPANION-002, a randomized phase II/III study, which will evaluate the safety and efficacy of CTX-009 in combination with paclitaxel versus paclitaxel alone as second-line treatment for patients with advanced biliary tract cancer. The primary end point is ORR, and crossover is allowed.Clinical Trial Registration: NCT05506943 (ClinicalTrials.gov).<BR>Looking for new options for patients with advanced biliary tract cancer? Explore COMPANION-002, Compass Therapeutics’ phase II/III study of CTX-009 + paclitaxel as a second line treatment.#CMPX #biotech #healthcare #rarecancer.